STRUCTURED ABSTRACT
Importance Algorithms for classification of inpatient COVID-19 severity are necessary for confounding control in studies using real-world data (RWD).
Objective To explore use of electronic health record (EHR) data to inform an administrative data algorithm for classification of supplemental oxygen or noninvasive ventilation (O2/NIV) and invasive mechanical ventilation (IMV) to assess disease severity in hospitalized COVID-19 patients.
Design In this retrospective cohort study, we developed an initial procedure-based algorithm to identify O2/NIV, IMV, and NEITHER O2/NIV nor IMV in two inpatient RWD sources. We then expanded the algorithm to explore the impact of adding diagnoses indicative of clinical need for O2/NIV (hypoxia, hypoxemia) or IMV (acute respiratory distress syndrome) and O2-related patient vitals available in the EHR. Observed changes in severity categorization were used to augment the administrative algorithm.
Setting Optum de-identified COVID-19 EHR data and HealthVerity claims and chargemaster data (March – August 2020).
Participants Among patients hospitalized with COVID-19 in each RWD source, our motivating example selected dexamethasone (DEX+) initiators and a random selection of patients who were non-initiators of a corticosteroid of interest (CSI-) matched on date of DEX initiation, age, sex, baseline comorbidity score, days since admission, and COVID-19 severity level (NEITHER, O2/NIV, IMV) on treatment index.
Main Outcome and Measures Inpatient COVID-19 severity was defined using the algorithms developed to classify respiratory support requirements among hospitalized COVID-19 patients (NEITHER, O2/NIV, IMV). Measures were reported as the treatment-specific distributions of patients in each severity level, and as observed changes in severity categorization between the initial procedure-based and expanded algorithms.
Results In the administrative data cohort with 5,524 DEX+ and CSI- patient pairs matched using the initial procedure-based algorithm, 30% were categorized as O2/NIV, 5% as IMV, and 65% as NEITHER. Among patients assigned NEITHER via the initial algorithm, use of an expanded algorithm informed by the EHR-based algorithm shifted 54% DEX+ and 28% CSI- to O2/NIV, and 2% DEX+ and 1% CSI- to IMV. Among patients initially assigned O2/NIV, 7% DEX+ and 3% CSI- shifted to IMV.
Conclusions and Relevance Application of learnings from an EHR-based exploration to our administrative algorithm minimized treatment-differential misclassification of COVID-19 severity.
Competing Interest Statement
This paper is part of a research collaboration agreement between the U.S. Food and Drug Administration (FDA) and Aetion, Inc. to use real-world data to advance the understanding and the natural history of coronavirus disease (COVID-19) in specific patient populations, as well as treatment and diagnostic patterns during the COVID-19 pandemic. This paper reflects the views of the authors and should not be construed to represent FDA's views or policies. EMG, ARW, SEV, IJE, JAR, and NMG are employees of Aetion, Inc., with stock options or existing equity.
Funding Statement
This paper is part of a research collaboration agreement between the U.S. Food and Drug Administration (FDA) and Aetion, Inc. to use real-world data to advance the understanding and the natural history of coronavirus disease (COVID-19) in specific patient populations, as well as treatment and diagnostic patterns during the COVID-19 pandemic.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the New England institutional review board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: This paper is part of a research collaboration agreement between the U.S. Food and Drug Administration (FDA) and Aetion, Inc. to use real-world data to advance the understanding and the natural history of coronavirus disease (COVID-19) in specific patient populations, as well as treatment and diagnostic patterns during the COVID-19 pandemic.
This paper reflects the views of the authors and should not be construed to represent FDA’s views or policies. EMG, ARW, SEV, IJE, JAR, and NMG are employees of Aetion, Inc., with stock options or existing equity.
Data Availability
Patient-level data belong to third parties and cannot be shared publicly. Upon reasonable request, researchers may obtain limited access to data and analytics infrastructure.
ABBREVIATIONS
- COVID-19
- coronavirus disease 19
- CPT
- current procedural terminology
- CSI
- corticosteroid of interest (DEX, methylprednisolone, prednisone, hydrocortisone)
- CSI-
- random selection of patients who had not (yet) initiated any CSI
- DEX
- dexamethasone
- DEX+
- dexamethasone initiators in the matched cohort
- ECMO
- extracorporeal membrane oxygenation
- EHR
- electronic health record
- FDA
- United States Food and Drug Administration
- HCPCS
- healthcare common procedure coding system
- ICD-10-CM
- international classification of disease codes, 10th revision, clinical modification
- ICD-10-PCS
- international classification of disease codes, 10th revision, procedural classification system
- IMV
- invasive mechanical ventilation
- mWHO
- modified version of WHO Clinical Progression Scale for COVID-19 severity
- NEITHER
- neither O2/NIV nor IMV
- NIV
- noninvasive ventilation
- O2
- oxygen/supplemental oxygen
- PaO2/FIO2
- ratio of arterial oxygen partial pressure to fractional inspired oxygen
- RWD
- real-world data
- SpO2
- blood oxygen saturation
- US
- United States
- WHO
- World Health Organization
